# Safety, Tolerability, and Pharmacokinetics of Single Rising Oral Doses of BIRB 1017 BS as a Solution in PEG 400 / 26% Ethanol Administered to Healthy Male Subjects

> **NCT02184338** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 48 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BIBR 1017 BS powder
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02184338
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-08
- **Primary completion:** 2004-11
- **Final completion:** —
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2014-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02184338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02184338, "Safety, Tolerability, and Pharmacokinetics of Single Rising Oral Doses of BIRB 1017 BS as a Solution in PEG 400 / 26% Ethanol Administered to Healthy Male Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02184338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*